ATAC Trial Steering Committee Membership Maroondah, VIC, Australia; Associate G Richardson, S Hart: Monash (Writing Committee denoted by *) Medical Centre, Melbourne, VIC, Australia; Associate G Toner, *M Baum (Chairman and Principal Investigator for the main ATAC P Francis: Peter MacCallum Cancer Institute, Melbourne, VIC, Australia; trial), University College London, London, UK; AR Bianco, Universita R Snyder, I Burns: St Vincents Hospital, Melbourne, VIC, Australia; Degli Studi Di Napoli Federico II, Napoli Italy; *AU Buzdar, The M Friedlander, D Goldstein: Prince of Wales Hospital, Randwick, University of Texas, M.D. Anderson Cancer Centre, Houston, USA; NSW, Australia; J Forbes, D Jackson: Newcastle Mater Hospital, M Coibion, Institut Bordet, Brussels, Belgium; *J Cuzick (Independent Waratah, NSW, Australia. statistician), Cancer Research UK, London, UK; M Dowsett, The Royal Belgium—A Makar, D Van den Weyngaert: AZ Middelheim, Antwerpen, Marsden Hospital, London, UK; WD George, Western Infirmary, Belgium; D Gangji, T Velu: Hôpital Erasme, Brussels, Belgium; Glasgow, UK; J Gray, Belfast City Hospital, Belfast, UK; *J Houghton, M Coibion, J-M Nogaret: Institut Bordet, Brussels, Belgium; P Neven, N Williams, Cancer Research UK and UCL Cancer Trials Centre, UCL Laurent: St Jan Ziekenhuis, Brussels, Belgium; J De Mol, F Van Aelst: Medical School, London, UK; A Howell, Christie Hospital and Holt Heilig Hart Ziekenhuis, Roeselare, Belgium. Radium Institute, Manchester, UK; *T Sahmoud, R Hellmund, Canada—SR Sehdev: Suite 102, 157 Queen Street East, Brampton, AstraZeneca Pharmaceuticals, Wilmington, USA; Ms L Thornton, Ontario, Canada; R Simard: Complexe Hospitalier de la Sagami, AstraZeneca Pharmaceuticals, Macclesfield, UK; JS Tobias, The Chicoutimi, Quebec, Canada; JR MacKey (J-M Nabholtz former PI): Meyerstein Institute of Clinical Oncology, Middlesex Hospital, Cross Cancer Institute, Edmonton, Alberta, Canada; J Dufresne: CUSE London, UK. (Fleurmont), Fleurmont, Quebec, Canada; WS Lofters: Kingston Regional Cancer Center, Kingston, Ontario, Canada; Holland: Lethbridge Cancer International Coordinating Committee Clinic, Lethbridge, Alberta, Canada; HL Solow: Markham Stouville AR Bianco, Universita degli Studi Di Napoli Federico II, Napoli, Italy; Health Centre, Markham, Ontario, Canada; JA Gapski: Trillium Health AU Buzdar, The University of Texas, MD Anderson Center, Houston, Centre, Mississauga, Ontario, Canada; SH Rubin (OR Keller former PI): TX, USA; M Coibion, Institut Bordet, Brussels, Belgium; M Constenla, South East Health Care Oncology Department, Moncton, New Hospital Montecelo, Pontevedra, Spain; W Distler, Frauenklinik Carl Brunswick, Canada; A Robidoux: CHUM Campus Hotel ñ Dieu, Gustav Carus Universitaet Dresden, Germany * J Forbes, Newcastle Montreal, Quebec, Canada; B Lesperance: Hospital Sacre Coeur, Mater Misericordiae Hospital, NSW, Australia; A Howell, Christie Montreal, Quebec, Canada; LC Panasci: McGill Department of Oncology, Hospital, Manchester, UK; WD George, Western Infirmary, Glasgow, Montreal, Quebec, Canada; LA Zibdawi: York County Hospital, UK; JP Guastalla, Centre Leon Berard, Lyon, France; * JGM Klijn, Newmarket, Ontario, Canada; J Chang: Lakeridge Health, Oshawa, Daniel den Hoed Cancer Centre and Erasmus University Medical Centre, Ontario, Canada; ML Brigden (D L Saltman former PI): Penticton Rotterdam, The Netherlands; GY Locker, Evanston Hospital, Kellogg Regional Hospital, Penticton, British Columbia, Canada; Cancer Care Center, Evanston IL, USA; RE Mansel, University of Wales RF Wierzbicki: Peterborough Regional Health Center Oncology Clinic, College of Medicine, Cardiff, UK; JM Nabholtz, University of California Peterborough, Ontario, Canada; BP Findlay: Hotel Dieu Hospital at Los Angeles, Los Angeles, CA, USA; T Nagykalnai, Uzsoki U Oncology Department, Quebec City, Quebec, Canada; J Robert: CHA Hospital, Budapest, Hungary; A Nicolucci, GIVIO Co-ordinating Centre, Pavillion St Sacrement, Quebec City, Quebec, Canada; S Lebel Consorzio Mario Negri Sud, Centro di Ricerche Farmacologiche e (M Potvin former PI): Hospital Laval, Quebec City, Quebec, Canada; Biomediche, S. Maria Imbaro, Italy; U Nylen, Radiumhemmet, MRBT Tirona: Allan Blair Cancer Center, Regina, Saskatchewan, Karolinska sjukhuset, Stockholm, Sweden; T Sahmoud, AstraZeneca Canada; MJ Burnell: Atlantic Health Sciences Corp, Saint John, New Pharmaceuticals, Wilmington, USA; R Sainsbury, Huddersfield Royal Brunswick, Canada; OR Keller (B A Walley former PI), Saskatoon Cancer Infirmary, Huddersfield, UK. Center, University of Saskatoon, Saskatoon, Saskatchewan, Canada; PLD Walde: Group Health Centre, Sault Ste Marie, Ontario, Canada; S-C Tang: H Bliss Murphy Cancer Centre, St Johns, Newfoundland, International Project Team Canada; CJ Germond: Northeastern Ontario Regional Can, Sudbury, E Foster, SCTN Central Office, Information and Statistics Division, Ontario, Canada; Y Rahim: Toronto East General Hospital, Toronto, Edinburgh, UK; Nicola Griffiths, AstraZeneca Pharmaceuticals, Ontario, Canada; JJ Wilson: Humber River Regional Hospital, Weston, Macclesfield, UK; J Houghton, N Williams, Cancer Research UK and Ontario, Canada; AL Cooke (D M Bowman former PI): Manitoba Cancer UCL Cancer Trials Centre, UCL Medical School, London, UK; Treatment and Research Foundation, Winnipeg, Manitoba, Canada. A Nicolucci, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy; S Czech Republic—K Petrakova, R Demlova: Masarykuv onkologicky ustav, Pollard, Northern Yorkshire Clinical Trials Research Unit, Leeds, UK; Brno, Czech Republic; P Vodvarka, T Kysela: FNsP Ostrava, Ostrava T Sahmoud, AstraZeneca Pharmaceuticals, Wilmington, USA; Poruba, Czech Republic; B Konopasek, P Mares: Vseobecna fakultni nemocnice, Praha, Czech Republic. Independent Data Monitoring Committee France—J-Edouard Mention: Centre de Gyneco-Obst, CHU, Amiens, M Buyse, International Institute for Drug Development (ID squared), France; D Serin, Y Goubely-Brewer: Clinique Ste Catherine, Avignon, Brussels, Belgium; R Margolese, Mc Gill University, The Sir Mortimer France; J-P Labat, J-P Malhaire: CHU Brest, Brest, France; G Devulder, B Davis Jewish General Hospital, Montreal, Quebec, Canada; JMA S Mirdat-Dako: Centre Hospitalier Laënnec, Creil, France; D Houze De Northover, ICRF Colorectal cancer unit, St Mark's Hospital, Harrow, L’Aunoit, J-Y Charvolin: Hôpital St Philibert, Lomme, France; Middlesex, UK. J-P Guastalla, T Bachelot: Centre Léon Bérard, Lyon, France; R Coquard, B Velay: Clinique St Jean, Lyon, France; C Lejeune, D Hadjadj-Aoul: Hôpital de la Conception, Marseille, France; Collaborative/Operational Groups M Untereiner, O Rixe: Hôpital-Clinique Claude Bernard, Metz, France; JF Forbes (Group Co-ordinator), JK Wakeham (Study Co-ordinator): F Laffargue, Hôpital Arnaud de Villeneuve, Montpellier, France; M Rios: Australian New Zealand Breast Cancer Trials Group Operations Office; Centre Alexis Vautrin, Nancy, France; J-M Vannetzel, R Mahjoubi: S de Placido (Study Co-ordinator), C Carlomagno (Study Co-ordinator), Centre Chirurgical Henri Hartmann, Neuilly sur Seine, France; Universita degli Studi Di Napoli Federico II, Italy; A Nicolucci (Group R Samak: Cabinet Medical, Nice, France; F Morvan, F Rousseau: Co-ordinator), M Belfiglio (Study Co-ordinator), M Valentini (Study Centre Hospitalier, Pontoise, France; C Veyret, JP Julien: Centre Henri Co-ordinator): GIVIO Group, Consorzio Mario Negri Sud, Italy; Becquerel, Rouen, France; B Cutuli, P Quetin: Centre Paul Strauss, L Foster (Trial Co-ordinator): Scottish Cancer Therapy Network Strasbourg, France; J-P Brettes, C Mathelin: HÙpital Civil, Strasbourg, (SCTN), Information & Statistics Division, Edinburgh, Scotland; France. M Tyrer (Trial monitor), R Catterick (Trial monitor): North West Breast Germany—W Distler, A Schindelhauer: Frauenklinik Carl Gustav Carus Group, Burnley, Lancashire, UK; S Pollard (Trial Co-ordinator): Universitaet Dresden, Germany; W Jaeger, G Wieland: Frauenklinik Northern & Yorkshire Clinical Trials Research Unit (NYCTRU), Friedrich-Alexander-Universitaet Erlangen-Nuernberg, Germany; University of Leeds, Leeds, UK; J Houghton (Senior Lecturer in Clinical C Oberhoff, D Hanisch: Zentrum f. Frauenheilkunde Trials), N Williams (Trial Co-ordinator): Cancer Research UK & UCL Universitaetsklinikum Essen, Germany; J Bechler, S Malur: Klink f. Cancer Trials Centre, London, UK. Frauenheilkunde u. Geburtshilfe FriedrichñSchiller Universitaet Jena, Germany; W Eiermann, G Raab: Frauenklinik vom Roten Kreuz, Principal and main co-investigators in the ATAC trial Muenchen, Germany. Argentina—F Coppola, C Bas: Hospital Aleman, Capital Federal, Buenos Hungary—C Polgar: National Oncology Institute, Budapest, Hungary; Aires, Argentina; J Itala, G Cortese: Hospital de Clinicas, Buenos Aires K Moskovits, Z Nagy: St Imre Hospital, Budapest, Hungary; University, Capital Federal, Buenos Aires, Argentina; A Nuñez de Pierro, T Nagykalnai, L Landherr: Uzsoki st. Hospital, Budapest, Hungary; D Allemand: Hospital Gral de Agudos-Juan Fernandez, Capital Federal, T Pinter, G Herodek: Petz Aladar Hospital, Gyor, Hungary; B Piko, Buenos Aires, Argentina; R Orti, R Testa: Hospital Italiano, Capital I Szegedi: Pandy Kalman County Hospital, Gyula, Hungary; J Szanto, Federal, Buenos Aires, Argentina; J Lebron, University of Buenos Aires, L Marazi: BAZ County Hospital, Miskolc, Hungary; Z Kahan: SZTE Capital Federal, Buenos Aires, Argentina Oncotherapy Clinic, Szeged, Hungary. Australia—G Gill, J Kollias: Royal Adelaide Hopsital, Adelaide,